公司資料
Biohaven 股價、新聞與催化劑
- 股票代碼:
- BHVN
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
13.14 USD (-1.57%)
收盤價
最後更新: 2026年10月1日
1.53B USD
市值
股價為何變動
截至 2026年10月1日，BHVN 下跌 1.57%，收於 $13.14。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Biohaven is a biopharmaceutical company focused on neuroscience, immunology, and rare disease. Its business combines commercial assets with a pipeline aimed at multiple specialty indications.
所在地與產業分類
Biohaven is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a strong neuroscience footprint.
商業模式特徵
The company depends on product sales, launch execution, and pipeline expansion across CNS and immune-mediated disease. Investors watch revenue, development milestones, and strategic execution.
生技產業定位
Biohaven occupies a premium specialty-biopharma niche within biotech. It has both commercial grounding and catalyst sensitivity, which keeps the stock lively.
未來催化劑
- Biohaven’s catalysts are its neuroscience pipeline, especially migraine and related CNS programs, plus any update that broadens the commercial story. The company remains one of the cleaner CNS growth names if execution holds.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。